m^(6)A RNA甲基化修饰在炎症性肠病中的研究进展  

Research progress of m^(6)A RNA methylation modification in inflammatory bowel disease

作　　者：杨理超 吴国涛 吴强 袁联文[1] Yang Lichao;Wu Guotao;Wu Qiang;Yuan Lianwen(Department of Geriatric Surgery,the Second Xiangya Hospital,Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院老年外科,长沙410011

出　　处：《中华炎性肠病杂志（中英文）》2022年第2期174-178,共5页Chinese Journal of Inflammatory Bowel Diseases

基　　金：国家自然科学基金(81970493);湖南省自然科学基金(2021JJ30973);中南大学中央高校基本科研业务费专项资金(2021zzts1060)。

摘　　要：炎症性肠病(IBD)是一种慢性肠道炎性疾病, 近年来研究发现m^(6)A甲基化修饰作为哺乳动物细胞中最丰富的mRNA修饰, 与IBD的发生发展有着密切关系。m^(6)A的关键酶(METTL3、METTL4、FTO等)不仅可以调控IBD中炎症、免疫的变化, 同时也能与肠道微环境有着双向反馈调节。本文综述m^(6)A RNA甲基化修饰在IBD中的研究进展, 旨在从表观遗传学层面深入了解IBD的发病机制, 为探索靶向m6A修饰相关蛋白来治疗IBD提供新方向。Inflammatory bowel disease(IBD)is a chronic inflammatory disorder of the intestine.In recent years,it has been found that m^(6)A methylation,as the most abundant mRNA modification in mammalian cells,is closely related to the occurrence and development of IBD.The key enzymes of m^(6)A(METTL3,METTL4,FTO,etc.)can not only regulate the changes of inflammation and immunity in IBD,but also have bidirectional feedback regulation with intestinal microenvironment.Therefore,this paper focuses on the research progress of m^(6)A RNA methylation modification in IBD in recent years,in order to deeply understand the pathogenesis of IBD from the epigenetic level,and provide a new direction for exploring targeted m^(6)A modification-related proteins to treat IBD in the future.

关 键 词：炎症性肠病 N6-甲基腺苷 炎症反应 免疫 肠道微生物 

分 类 号：R574[医药卫生—消化系统]